Amanda Copeland1, Anas Younes. 1. Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Abstract
PURPOSE OF REVIEW: This review will focus on monoclonal antibodies and small molecule inhibitors used in the treatment of newly diagnosed and relapsed/refractory classical Hodgkin lymphoma. RECENT FINDINGS: Development of novel therapies is highly needed to improve treatment outcome of relapsed patients. New agents have shown to be effective and safe suggesting their use in combination with conventional therapy or with other targeted therapies in frontline and salvage regimens. SUMMARY: Approximately 9000 new cases of Hodgkin lymphoma will be diagnosed in 2012, representing 11% of all lymphomas in the USA. Although considered a highly curable malignancy, a third of patients will not respond to or relapse after initial therapy. Second-line therapy typically includes multiagent chemotherapy regimens followed by autologous stem cell transplantation. Patients whose disease relapses after autologous stem cell transplantation have poor prognosis, with a median survival of less than 3 years.
PURPOSE OF REVIEW: This review will focus on monoclonal antibodies and small molecule inhibitors used in the treatment of newly diagnosed and relapsed/refractory classical Hodgkin lymphoma. RECENT FINDINGS: Development of novel therapies is highly needed to improve treatment outcome of relapsed patients. New agents have shown to be effective and safe suggesting their use in combination with conventional therapy or with other targeted therapies in frontline and salvage regimens. SUMMARY: Approximately 9000 new cases of Hodgkin lymphoma will be diagnosed in 2012, representing 11% of all lymphomas in the USA. Although considered a highly curable malignancy, a third of patients will not respond to or relapse after initial therapy. Second-line therapy typically includes multiagent chemotherapy regimens followed by autologous stem cell transplantation. Patients whose disease relapses after autologous stem cell transplantation have poor prognosis, with a median survival of less than 3 years.
Authors: Maika Onishi; Solomon A Graf; Leona Holmberg; Sanaz Behnia; Andrei R Shustov; Karen Schiavo; Mary Philip; Edward N Libby; Ryan D Cassaday; John M Pagel; Jennifer E Roden; David G Maloney; Damian J Green; Brian G Till; Oliver W Press; Stephen D Smith; Ajay K Gopal Journal: Hematol Oncol Date: 2014-09-18 Impact factor: 5.271
Authors: Mathias Gehrmann; Stefan Stangl; Gemma A Foulds; Rupert Oellinger; Stephanie Breuninger; Roland Rad; Alan G Pockley; Gabriele Multhoff Journal: PLoS One Date: 2014-08-28 Impact factor: 3.240